U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1916
    -0.0063 (-0.52%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • USD/JPY

    108.3600
    +0.3840 (+0.36%)
     
  • BTC-USD

    50,686.99
    +2,626.99 (+5.47%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Recap: Amgen Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Amgen (NASDAQ:AMGN) decreased in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 4.67% year over year to $3.81, which beat the estimate of $3.39.

Revenue of $6,634,000,000 up by 7.05% from the same period last year, which beat the estimate of $6,580,000,000.

Looking Ahead

Amgen Sees FY21 Adj. EPS $16-$17 vs $17.02 Est., Sales $25.8B-$26.6B vs $26.43B Est.

How To Listen To The Conference Call

Date: Feb 02, 2021

Time: 05:00 PM

View more earnings on AMGN

ET Webcast URL: https://edge.media-server.com/mmc/p/wb6iw2o7

Price Action

Company's 52-week high was at $276.69

52-week low: $177.05

Price action over last quarter: Up 8.12%

Company Profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.